第十一批药品集采规则全面优化：稳临床、保质量双管齐下

Core Viewpoint - The 11th batch of national organized drug procurement is set to optimize rules focusing on "stabilizing clinical use, ensuring quality, preventing collusion, and countering excessive competition" Group 1: Clinical Stability and Quality Assurance - A total of 46,000 medical institutions participated in this procurement, allowing them to report brands based on clinical usage habits [1] - Special attention is given to the supply of pediatric medications, with price adjustments for small-sized oral solutions and injectable forms suitable for children [1] Group 2: Quality Control and Bidding Requirements - The procurement process imposes higher quality control standards, requiring bidders or their contracted manufacturers to have at least 2 years of production experience for similar dosage forms [3] - Preference will be given to enterprises recognized for clinical use and stable quality [3] - Measures to prevent collusion have been enhanced, and bidders must commit to pricing not lower than their costs; those bidding below 50% of the average entry price must justify their pricing [3] Group 3: Execution of Selected Results - Selected enterprises are designated as the primary responsible parties for supply assurance, required to respond promptly to medical institution orders and complete deliveries [5] - Medical institutions are expected to prioritize the procurement of selected products and adhere to agreed purchasing volumes and timely payment obligations [5]